[1] Global HIV & AIDS statistics — Fact sheet. https://www.unaids.org/en/resources/fact-sheet. [2023-4-20].
[2] Liu X, Wang D, Hu J, Song C, Liao LJ, Feng Y, et al. Changes in HIV-1 subtypes/sub-subtypes, and transmitted drug resistance among ART-Naïve HIV-infected individuals — China, 2004-2022. China CDC Wkly 2023;5(30):664 − 71. https://doi.org/10.46234/ccdcw2023.129CrossRef
[3] World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. Geneva: World Health Organization; 2019. https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15.
[4] AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018). Chin J Intern Med 2018;57(12):867 − 884. https://doi.org/10.3760/cma.j.issn.0578-1426.2018.12.002CrossRef
[5] The People’s Health Press Co., Ltd. National free AIDS antiviral treatment manual. 5th ed. Beijing: The People’s Health Press Co., Ltd. 2023. http://books.ipmph.com/books/detail/2049011.shtml. (In Chinese). 
[6] Liu LF, Dai LL, Yao J, Pan PL, Li L, Liu ZY, et al. Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naïve individuals in a tertiary care hospital in Beijing, China. AIDS 2019;33(12):1945 − 47. https://doi.org/10.1097/QAD.0000000000002282CrossRef
[7] Yin YQ, Lu J, Zhou Y, Shi LE, Yuan DF, Chen JS, et al. Drug resistance to HIV-1 Integrase inhibitors among treatment-naive patients in Jiangsu, China. Biomed Environ Sci 2021;34(5):400 − 3. https://doi.org/10.3967/bes2021.053CrossRef
[8] Zhang HZ, Wu P, Li JG, Li M. Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China. Virulence 2023;14(1):2278254. https://doi.org/10.1080/21505594.2023.2278254CrossRef
[9] Sun PY, Chen HC, Dai J, Dong LJ, Jin XM, Yang M, et al. Characteristics of HIV-1 integrase inhibitor resistance and molecular networks among men who have sex with men in Kunming city, 2019-2020. Chin J AIDS STD 2023;29(4):448 − 52. https://doi.org/10.13419/j.cnki.aids.2023.04.17CrossRef
[10] Hu HP, Hao JJ, Liu X, Chen HL, Hu J, Song C, et al. Prevalence of HIV-1 integrase inhibitor resistance before antiviral therapy in some provinces of China in 2022. Int J Virol 2024;31(4):265 − 9. https://doi.org/10.3760/cma.j.issn.1673-4092.2024.04.001CrossRef
[11] Song C, Zhou JJ, Dong AB, Kang RH, Ruan YH, Shao YM, et al. A survey on integrase inhibitor related resistance in HIV-infected persons before antiretroviral treatment in China in 2018. Chin J AIDS STD 2021;27(4):348 − 51. https://doi.org/10.13419/j.cnki.aids.2021.04.05CrossRef
[12] Zhang HZ, Wu P, Li JG, Li M. Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China. Virulence 2023;14(1):2278254. http://dx.doi.org/10.1080/21505594.2023.2278254.
[13] Zhu Y, Huang YM, Zheng CL, Tang J, Zeng G, Xie W, et al. Primary resistance to integrase inhibitors in Shenzhen. J Antimicrob Chemother 2023;78(2):546 − 9. https://doi.org/10.1093/jac/dkac442CrossRef
[14] Chen GJ, Cheng CY, Yang CJ, Lee NY, Tang HJ, Huang SH, et al. Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan. J Antimicrob Chemother 2024;79(5):1157 − 63. https://doi.org/10.1093/jac/dkae086CrossRef
[15] Muccini C, Galli L, Sampaolo M, Gianotti N, Castagna A, Canetti D. Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV. J Antimicrob Chemother 2023;78(5):1314 − 5. https://doi.org/10.1093/jac/dkad109CrossRef
[16] De Salazar A, Viñuela L, Fuentes A, Teyssou E, Charpentier C, Lambert-Niclot S, et al. Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in Mediterranean Europe. Clin Infect Dis 2023;76(9):1628 − 35. https://doi.org/10.1093/cid/ciac972CrossRef
[17] Viñuela L, De Salazar A, Fuentes A, Serrano-Conde E, Falces-Romero I, Pinto A, et al. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019-2021. J Med Virol 2023;95(12):e29287. https://doi.org/10.1002/jmv.29287CrossRef
[18] Ferrer P, Ramos V, Puente M, Afani A. Preliminary report of transmitted drug resistance to integrase strand chain transfer inhibitors in treatment-naïve HIV infected patients. Diagn Microbiol Infect Dis 2023;107(4):116083. https://doi.org/10.1016/j.diagmicrobio.2023.116083CrossRef
[19] Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012;86(5):2696 − 705. https://doi.org/10.1128/JVI.06591-11CrossRef
[20] Appah A, Beelen CJ, Kirkby D, Dong W, Shahid A, Foley B, et al. Molecular epidemiology of HIV-1 in Ghana: subtype distribution, drug resistance and Coreceptor usage. Viruses 2022;15(1):128. https://doi.org/10.3390/v15010128CrossRef
[21] Zhou C, Liang S, Li YP, Zhang Y, Li L, Ye L, et al. Characterization of HIV-1 molecular epidemiology and transmitted drug-resistance in newly diagnosed HIV-infected patients in Sichuan, China. BMC Infect Dis 2022;22(1):602. https://doi.org/10.1186/s12879-022-07576-zCrossRef